Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo aims to ease myasthenia gravis symptoms

NCT ID NCT07294170

Disease control Sponsor: argenx Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Sep 18, 2026 · Updated 6 times

Summary

This study is testing two drugs, efgartigimod and empasiprubart, given by IV, to see if they are safe and work well for people with myasthenia gravis (MG). The goal is to reduce side effects and improve quality of life. About 70 adults with MG are being recruited.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Efgartigimod and empasiprubart (given as intravenous infusions)
What this could lead to
If successful, this could point toward better treatment options for myasthenia gravis with fewer side effects and improved quality of life.
What could go wrong
This is an early Phase 2a proof-of-concept study with only 70 participants, so results may not apply to everyone. The drugs may not work as hoped or could cause unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 70 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2025

Expected to finish

Mar 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Is at least 18 years of age and the local legal age of consent for clinical studies * Has been diagnosed with MG with consistent clinical features per the investigator's clinical judgment * If receiving MG therapy, including nonsteroidal immunosuppressive drugs (NSIDs), corticosteroids, or acetylcholinesterase (AChE) inhibitors either in combination or alone, the participant should receive a stable dosage before master protocol screening Exclusion Criteria: * Known autoimmune disease or any medical condition other than the indication under study that would interfere with an accurate assessment of clinical symptoms of MG or puts the participant at undue risk * Is MGFA (Myasthenia Gravis Foundation of America) Class V

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Achr-ab seropositive generalized myasthenia gravis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

myasthenia gravis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Achr-ab seropositive generalized myasthenia gravis Generalized myasthenia gravis Generalized myasthenia gravis (GMG) GMG MG Myasthenia gravis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    30 sites in 8 countries. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • AHEPA University General Hospital of Thessaloniki

    RECRUITING

    Thessaloniki, 546 36, Greece

    Contact Email: •••••@•••••

  • AORN Antonio Cardarelli

    RECRUITING

    Naples, 80131, Italy

  • ASST Papa Giovanni XXIII - Ospedale Papa Giovanni XXIII

    RECRUITING

    Bergamo, Lombardy, 24127, Italy

    Contact Email: •••••@•••••

  • Centrum Medyczne Neurologia Slaska

    RECRUITING

    Katowice, Silesian Voivodeship, 40-689, Poland

  • Charité - Universitätsmedizin Berlin

    RECRUITING

    Berlin, 13353, Germany

    Contact Email: •••••@•••••

  • Dent Neurologic Institute - Amherst

    RECRUITING

    Amherst, New York, 14226, United States

  • Duke Early Phase Clinical Research Unit - PPDS

    RECRUITING

    Durham, North Carolina, 27710-0001, United States

    Contact Email: •••••@•••••

  • Eginitio Hospital

    RECRUITING

    Athens, 115 28, Greece

    Contact Email: •••••@•••••

  • Erlanger Health System

    RECRUITING

    Chattanooga, Tennessee, 37403-2136, United States

  • Fondazione IRCCS Istituto Neurologico Carlo Besta

    RECRUITING

    Milan, Lombardy, 20133, Italy

    Contact Email: •••••@•••••

  • Fondazione IRCCS Istituto Neurologico Carlo Besta

    RECRUITING

    Milan, 20133, Italy

    Contact Email: •••••@•••••

  • General Hanamaki Hospital - Kajomachi

    RECRUITING

    Hanamaki, 025-0075, Japan

  • Henry Ford Health System

    RECRUITING

    Detroit, Michigan, 48202-2608, United States

    Contact Email: •••••@•••••

  • Hospital Regional Universitario de Malaga - Hospital General

    RECRUITING

    Málaga, Malaga, 340120, Spain

  • Hospital de La Santa Creu i Sant Pau

    RECRUITING

    Barcelona, 8041, Spain

    Contact Email: •••••@•••••

  • IUHW Narita Hospital

    RECRUITING

    Narita, 286-8520, Japan

  • Krakowska Akademia Neurologii Sp. z o.o.

    RECRUITING

    Krakow, Lesser Poland Voivodeship, 31-505, Poland

  • MICS Centrum Medyczne Bydgoszcz

    RECRUITING

    Bydgoszcz, Kuyavian-Pomeranian Voivodeship, 85-065, Poland

  • Massachusetts General Hospital

    RECRUITING

    Boston, Massachusetts, 02114-2621, United States

  • National Hospital Organization Sendai Medical Center

    ACTIVE_NOT_RECRUITING

    Sendai, Miyagi, 983-0045, Japan

  • National Neuromuscular Research Institute

    RECRUITING

    Austin, Texas, 78759, United States

  • Ohio State Martha Morehouse Outpatient Care

    RECRUITING

    Columbus, Ohio, 43221-3502, United States

  • Profound Research LLC - Carlsbad

    RECRUITING

    Carlsbad, California, 92011, United States

  • Profound Research LLC at Las Vegas Neurology Center

    ACTIVE_NOT_RECRUITING

    Las Vegas, Nevada, 89106, United States

  • St. Marianna University Hospital

    ACTIVE_NOT_RECRUITING

    Kawasaki-Shi, Kanagawa, 216-8511, Japan

  • UZ Leuven - PPDS

    RECRUITING

    Leuven, 3000, Belgium

  • University of North Carolina at Chapel Hill-170 Manning Dr.

    ACTIVE_NOT_RECRUITING

    Chapel Hill, North Carolina, 27514-4221, United States

  • University of South Florida

    RECRUITING

    Tampa, Florida, 33620, United States

  • University of Texas- San Antonio - Health Science Center - PPDS

    RECRUITING

    San Antonio, Texas, 78229, United States

  • University of Tsukuba Hospital

    ACTIVE_NOT_RECRUITING

    Tsukuba, Ibaraki, 305-8576, Japan

  • Universitätsklinikum Würzburg

    RECRUITING

    Würzburg, 97080, Germany

  • Universitätsmedizin Göttingen

    RECRUITING

    Göttingen, 37075, Germany

  • Visionary Investigators Network

    RECRUITING

    Miami, Florida, 33133, United States

  • Visionary Investigators Network

    RECRUITING

    Miami, Florida, 33180, United States

    Contact Email: •••••@•••••

  • Warszawski Uniwersytet Medyczny

    RECRUITING

    Warsaw, 00-665, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.